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LETTERS TO THE EDITOR 
CLOZAPINE FOR PSYCHOTIC AND 
BEHAVIOURAL PROBLEMS IN DEMENTIA 
Sir, 
Psychotic and behavioural abnormalities 
are common in dementia. Typical neuroleptics 
are extensively used for such disorders. Their 
use is attended with several severe side effects 
(McKeith et al.,1992). It was noted that the 
experience with atypical antipsychotics, which 
have lesser adverse effects, for treatment of 
agitation and other behavioural problems in the 
demented elderly patients is extremely limited 
(Mintzer&Brawman-Mintzer, 1996). Neuroleptic 
sensitivity has been reported in the use of 
atypical neuroleptic like risperidone in dementia 
patients but not with clozapine (McKeith et 
al.,1995; Ballard eta!., 1998) It seems that among 
the newer atypical antipsychotics, clozapine is 
probably more safe for use in dementia. 
Clozapine was used effectively by the 
author in small doses for four patients of 
dementia with severe psychiatric symptoms and 
is reported here. The observation was made in 
four patients who presented with picture of 
dementia of a subacute/chronic nature and more 
recent psychiatric disturbances. Three of them 
were elderly patients with a clinical diagnosis of 
dementia of Alzheimer's type and one was a 
younger patient suffering from alcoholic 
dementia. The psychiatric symptoms consisted 
of insomnia, refusing to eat food, restlessness, 
wandering, shouting, abusive talk, irrelevant talk, 
hitting oneself, paranoid delusions, hallucinations 
and disinhibited behaviour. 
Clozapine was given in doses ranging 
from 12.5 mg to 50 mg per day and the duration 
of treatment ranged from 2 months to six months. 
The necessary evaluation and monitoring of the 
haemogram was done as required, The starting 
of response to clozapine was immediate in all 
the patients. The commonly featunng symptoms 
of insomnia and loud talk improved after the first 
dose of the drug. Most of the other behavioural 
problems remitted fully in 4 to 6 weeks period. 
The overall degree of improvement in the clinical 
picture was rated as moderate to marked by the 
family members on a visual analog scale for 
three patients and as mild for one patient. 
Clozapine was discontinued for one of the 
patients after 2 months as she was feeling very 
drowsy and it "was replaced by bedtime dose of 
25 mg of thioridazine. 
Clozapine in low doses thus could be 
an effective and safe alternative to typical 
neuroleptics for controlling severe psychiatric 
manifestations in dementia patients The 
advantage of clozapine lies in its reduced risk 
for developing tardive dyskinesia and cognitive 
dysfunction, especially for the aged patients. 
With the necessary precautions the drug could 
be considered for use for severe psychiatric 
symptoms in dementia in selected subjects 
where other drugs were ineffective or caused 
severe adverse effects. 
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